Johnson & Johnson $2.2 Billion Settlement (2013)

The government accused Johnson & Johnson of a broad scheme to boost profits through deceptive marketing of its antipsychotic drugs. The misconduct involved pushing medications for uses never approved by regulators and offering improper payments to drive prescriptions.

– J&J promoted two drugs for off-label uses in elderly patients, including dementia and Alzheimer’s disease, despite FDA approval only for schizophrenia and bipolar disorder
– The company allegedly paid kickbacks to physicians and nursing home pharmacies to encourage prescribing and distribution of its drugs
– These practices resulted in false claims submitted to Medicare, Medicaid, and other federal healthcare programs

The Johnson & Johnson settlement totaled more than $2.2 billion. The resolution included criminal fines and civil settlements.

– The criminal component was $485 million, which included criminal fines and forfeiture. This stemmed from a subsidiary’s guilty plea to misbranding Risperdal
– The civil component was $1.72 billion, which resolved False Claims Act allegations with the federal government and 45 states

The J&J settlement was driven by multiple whistleblowers who filed separate qui tam lawsuits across different states. Their collective insider knowledge exposed the company’s off-label marketing and kickback schemes, providing the government with the evidence needed to build its case.

– Five whistleblowers filed four qui tam lawsuits in the Eastern District of Pennsylvania, which were consolidated into the government’s investigation
– Joe Strom, a former employee of J&J subsidiary Scios, filed suit in 2005 and received $28 million for his role in exposing misconduct
– The whistleblowers collectively received a record $167.7 million award, one of the largest in U.S. history

The Johnson & Johnson case involved multiple prescription drugs at the center of the off-label marketing and kickback allegations. The misconduct spanned antipsychotic medications and a heart failure drug.

– Risperdal (risperidone): An antipsychotic drug promoted for unapproved uses in elderly dementia patients and children, despite significant safety risks
– Invega (paliperidone): A newer antipsychotic medication also promoted off-label for unapproved conditions and patient populations
– Natrecor (nesiritide): A heart failure drug that was unlawfully promoted for off-label, unapproved uses

The Johnson & Johnson case reinforced compliance standards and added new accountability layers. The five-year Corporate Integrity Agreement required enhanced training, independent monitoring, and strict sales oversight. J&J also separated sales compensation from prescription volume, removing the incentive for improper promotion.

Most significantly, the case expanded government reach into nursing homes, as J&J paid kickbacks to facilities to encourage Risperdal prescriptions. This prompted widespread reforms in long-term care prescribing and heightened scrutiny of pharmaceutical relationships with nursing homes.

The whistleblowers in the J&J case took substantial risks to expose the company’s misconduct. They documented illegal practices, preserved evidence, and filed qui tam lawsuits that launched the government investigation.

– Gregory Thorpe, a former sales manager, documented off-label promotion of Risperdal and contacted the FDA before filing his suit
– Joe Strom, a former employee of subsidiary Scios, filed a separate lawsuit after witnessing illegal marketing of Natrecor and provided internal documents to the government
– Other whistleblowers reported kickback schemes involving nursing home pharmacies, providing evidence that expanded the case

These coordinated actions gave the government the evidence to intervene and secure the record settlement.

The Johnson & Johnson settlement is a landmark because it was the third largest healthcare fraud recovery in U.S. history and featured the largest whistleblower award ever at $167.7 million.

The case expanded the government’s enforcement reach into nursing homes, exposing kickback schemes targeting vulnerable elderly patients.

The $1.72 billion civil component included participation from 45 states, demonstrating unprecedented federal-state coordination. The case also reinforced that off-label marketing and kickbacks would be met with severe consequences, further solidifying the False Claims Act as the government’s most powerful tool against pharmaceutical fraud.